Randomized study of traditional versus aggressive systolic blood pressure control (Cardio-Sis): Rationale, design and characteristics of the study population

Journal of Human Hypertension

Volumn 22, Issue 4, 2008, Pages 243-251

  Verdecchia, Paolo ^a   Staessen, Jan A ^a   Achilli, Augusto ^a   de Simone, Giovanni ^a   Ganau, Antonello ^a   Mureddu, Gianfrancesco ^a   Pede, Sergio ^a   Porcellati, Carlo ^a   Fornari, Giovanni ^a   Repaci, S ^a   Castellani, C ^a   Achilli, P ^a   Jaspers, C ^a   Cucchiara, G ^a   Panzano, C ^a   Angeli, F ^a   Aillon, C ^a   Sclavo, M G ^a   Scherillo, M ^a   Raucci, D ^a   Di Donato, M ^a   Cas, L D ^a   Faggiano, P ^a   Porcu, M ^a   Calamida, R ^a   Pistia, L ^a   Vancheri, F ^a   Alletto, M ^a   Curcio, M ^a   Pettinati, G ^a   Ieva, M ^a   Muscella, A ^a   Guerrieri, M ^a   Denbek, C ^a   Gulizia, M ^a   Francese, G M ^a   Perticone, F ^a   Iemma, G ^a   Fariello, R ^a   Sala, N ^a   Mezzetti, A ^a   Pierdomenico, S D ^a   Bucci, M ^a   Benemio, G ^a   Gattobigio, R ^a   Sacchi, N ^a   Cocchieri, M ^a   Prosciutti, L ^a   Battocchi, P ^a   Garognoli, O ^a   Arcelli, G ^a   Pirelli, S ^a   Emanuelli, C ^a   Braschi, G B ^a   Abrignani, M ^a   De Ferrari, G ^a   Ponremoli, R ^a   Igidbashian, D ^a   Marini, R ^a   Scarpino, L ^a   Mandorla, S ^a   Buccolieri, M ^a   Picchi, L ^a   Casolo, G ^a   Pardini, M ^a   Marracci, G ^a   Strazzullo, P ^a   Galletti, Ferruccio ^a   Barbato, A ^a   Cavallini, C ^a   Borgioni, C ^a   Seghieri, G ^a   Cipollini, F ^a   Arcangeli, E ^a   Boddi, W ^a   Palermo, C ^a   Savelli, F ^a   Lembo, G ^a   Vecchione, C ^a   Malatino, L ^a   Belluardo, P ^a   Zoccali, C ^a   Leonardis, D ^a   Mallamaci, F ^a   Lacche A ^a   Gentile, C ^a   Boccanelli, A ^a   Mureddu, G F ^a   Santini, M ^a   Colivicchi, F ^a   Ficili, S ^a   Uguccioni, M ^a   Nardozi, C ^a   Tedeschi, A ^a   Martin, G ^a   Zanata, G ^a   Mos, L ^a   Dialti, V ^a   Martina, S ^a   Pede, S ^a   Renna, A ^a   Ganau, A ^a   Farina, G ^a   Tripodi, E ^a   Miserrafiti, B ^a   Scali, R ^a   Stornello, M ^a   Valvo, E ^a   Bernardinangeli, M ^a   Proietti, G ^a   Poddighe, G ^a   Biscottini, B ^a   Panciarola, R ^a   Boccali, A ^a   Veglio, F ^a   Rabbia, F ^a   Caserta, M ^a   Chiatto, M ^a   Stefenelli, C ^a   Cioffi, G ^a   Bonazza, G ^a   Scabbia, E V ^a   Achilli, A ^a   Bottoni, D ^a   more..

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BISOPROLOL; CLONIDINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; RAMIPRIL; TELMISARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG RESPONSE; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 41049088706     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002313     Document Type: Article

References (29)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JLJ, et al., Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
3. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-1966.
4. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood-pressure control in the hypertensive population. Lancet 1997; 349: 454-457.
5. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol in the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3: 379-392.
6. Isles CG, Waker LM, Beevers GD, Brown I, Cameron HL, Clarke J et al Mortality in patients in the Glasgow blood pressure clinic. J Hypertens 1986; 4: 141-156.
7. Bulpitt CJ, Bevers DG, Butler A, Coles EC, Fletcher AE, Hunt D et al Treated blood pressure, rather than pretreatment, predicts survival in hypertensive patients. A report from the DHSS Hypertension Care Computing Project. J Hypertens 1988; 6: 627-632.
8. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360 1903-1913.
9. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
10. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al., African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288: 2421-2431.
11. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 Suppl 2): B54-B64.
12. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS38. BMJ 1998; 317: 703-713.
13. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: The Framingham Study. Ann Intern Med 1970; 72: 813-822.
14. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786-1793.
15. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, et al., Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104: 1615-1621.
16. Verdecchia P, Reboldi GP, Angeli F, Avanzini F, de Simone G, Pede S et al., on behalf of the HEART Survey Study Group. Prognostic value of serial electrocardiographic voltage and repolarization changes in essential hypertension. The HEART Survey Study. Am J Hypertens 2007; 20: 997-1004.
17. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Guerrieri M, Zampi I et al. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol 1994; 74: 714-719.
18. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J Am Coll Cardiol 1998; 31: 383-390.
19. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969.
20. Cox DR. Regression models and life-tables. J R Stat Soc (B) 1972; 34: 187-220.
21. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Rocella EJ, Levy D. Differential control of systolic and diastolic blood pressure. Factors associated with lack of blood pressure control in the community. Hypertension 2000; 36: 594-599.
22. Rutan G, McDonald RH, Kuller RH. A historical perspective of elevated systolic versus diastolic blood pressure from an epidemiological and clinical trial viewpoint. J Clin Epidemiol 1989; 42: 663-673.
23. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF et al. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-592.
24. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al., LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292: 2343-2349.
25. Devereux RB, Agabiti Rosei E, Dahlof B, Gosse P, Hahn RT, Okin PM, Roman MJ. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens Suppl 1996; 14: S95-S101.
26. Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlöf B, for the LIFE Study Group. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients. The Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension 2000; 35: 13-18.
27. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al., VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-2031.
28. Verdecchia P, Palatini P, Schillaci G, Mormino P, Porcellati C, Pessina AC. Independent predictors of isolated clinic ('white-coat') hypertension. J Hypertens 2001; 19: 1015-1020.
29. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-1419.